After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is ...
Novo Nordisk shares have slipped over 2% premarket on Thursday after the company made an unsolicited bid to acquire Metsera, a U.S. obesity drug developer, in a move BMO Capital described as “an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback